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Abstract
We conducted an epidemiologic investigation among survivors of an outbreak of Middle East 
respiratory syndrome coronavirus (MERS-CoV) infection in Jordan. A second-trimester stillbirth 
occurred during the course of an acute respiratory illness that was attributed to MERS-CoV on the 
basis of exposure history and positive results of MERS-CoV serologic testing. This is the first 
occurrence of stillbirth during an infection with MERS-CoV and may have bearing upon the 
surveillance and management of pregnant women in settings of unexplained respiratory illness 
potentially due to MERS-CoV. Future prospective investigations of MERS-CoV should ascertain 
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pregnancy status and obtain further pregnancy-related data, including biological specimens for 
confirmatory testing.
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New cases and clusters of Middle East respiratory syndrome coronavirus (MERS-CoV) 
infections continue to occur sporadically in the Middle East, Arabian Peninsula, and Europe 
[1]. MERS-CoV is a novel coronavirus known to cause acute respiratory illness typically 
associated with fever, which can progress rapidly to respiratory failure and, in some patients, 
renal failure. There has been no information yet published regarding the impact of MERS-
CoV infections on pregnancy outcomes.
METHODS
In May 2013, epidemiologists from the Centers for Disease Control and Prevention (CDC) 
joined the Jordan Ministry of Health and regional partners to conduct a retrospective 
investigation of an April 2012 outbreak of respiratory illness, using newly developed 
serologic tests for detection of MERS-CoV antibodies. After the discovery of MERS-CoV, 
retrospective diagnoses of MERS-CoV infection were assigned to 2 individuals who died 
during this outbreak, based on findings of real-time reverse-transcription polymerase chain 
reaction (RT-PCR), and were reported to the World Health Organization (WHO).
Serum specimens were collected and epidemiologic data were obtained from potentially 
exposed groups, including outbreak survivors and household contacts, through medical chart 
reviews and interviews. Household members were considered eligible for enrollment if they 
reported usually sleeping under the same roof as an outbreak member during the outbreak 
period, which lasted from February through April 2012. The initial outbreak case definition 
included “any case admitted [to the hospital] or their close contacts, who complained of 
fever and dry cough with radiological evidence of pneumonia during the period from 15 
March to 30 April,” which identified 13 individuals, including the 2 fatal cases [2].
Interviews focused on a range of topics, including the history of illness, detailed contact 
history (with surviving outbreak group members, the household members of outbreak group 
members, visiting travelers, and animals), travel history, and occupation.
MERS-CoV antibody positivity was defined as a positive result of the HKU5.2N enzyme 
immunoassay (EIA) [plasmid provided by the University of Hong Kong, courtesy of Dr. 
Susanna Lau] and a correlated positive result of either the MERS-CoV immunofluorescence 
assay (IFA) or the MERS-CoV_(Hu/Jordan-N3/2012) microneutralization titer assay (MNt) 
developed at the CDC.
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During the course of the MERS-CoV outbreak investigation in Zarqa, Jordan, we obtained 
data and specimens from 11 subjects in the initial outbreak group and from 26 subjects who 
resided in the same households as subjects in the initial outbreak group during the outbreak 
period. One household was lost to follow-up, and 1 did not consent for participation. Six of 
these 37 subjects (16%) were women aged 18–45 years. Three (50%) reported being 
pregnant during the outbreak period. Two of the pregnancies reportedly resulted in 
miscarriage, but both mothers tested negative for MERS-CoV antibody.
The third pregnant woman, aged 39 years, had a stillbirth at approximately 5 months of 
gestation, and her laboratory results were positive for MERS-CoV antibody by EIA (titer, 
1:1600), IFA, and MNt (titer, 80). During the outbreak period, her acute respiratory 
symptoms (fever, rhinorrhea, fatigue, headache, and cough) occurred concurrently with 
vaginal bleeding and abdominal pain on the seventh day of illness, and she spontaneously 
delivered a stillborn infant.
The pregnant subject’s onset of respiratory symptoms occurred 7 days following the onset of 
her husband’s symptomatic acute respiratory illness; he also tested positive for MERS-CoV 
antibodies by all 3 serologic tests (EIA titer, 1:400; IFA, MNt titer, 40). Additionally, she 
had another close relative who died of a MERS-CoV infection, confirmed by real-time RT-
PCR, 1 day before the date of onset of the pregnant subject’s symptoms. The pregnant 
subject reported having unprotected exposures to both of these family members during their 
symptomatic MERS-CoV illnesses (Figure 1).
The pregnant subject refused medical care during her illness because of stated concerns 
about undergoing chest radiography and receiving medications during pregnancy. As is 
common in this region, fetal specimens were not retained and were not available for 
retrospective evaluation. Before her stillbirth, she received regular antenatal care with a 
physician and had no reported complications during pregnancy. Including the recent 
stillbirth, she had had 7 pregnancies, resulting in 6 full-term live births. The surviving 6 
children tested negative for MERS-CoV antibodies.
DISCUSSION
We report a second trimester stillbirth in a pregnant subject who had a concurrent acute 
respiratory illness that met the WHO case definition for probable MERS-CoV infection [3]. 
Linked to the Jordanian outbreak of MERS-CoV infection, the illness in the pregnant subject 
began within 14 days following unprotected exposures to 2 individuals with MERS-CoV 
during their illnesses (her MERS-CoV antibody–positive husband and a real-time RT-PCR–
positive relative). She was symptomatic but did not seek medical care because she wished to 
avoid chest radiography and medications during pregnancy.
With the currently limited knowledge about MERS-CoV epidemiology and 
pathophysiology, it is prudent to review observed associations between pregnancy outcomes 
and other severe respiratory pathogens. Complications such as maternal mortality and 
stillbirth have been reported among pregnant women with severe respiratory infections 
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caused by SARS coronavirus (SARS-CoV) [4], influenza A virus subtype H1N1 [5, 6], and 
other viruses causing pneumonia [7]. Uncomplicated pregnancies lead to physiologic 
changes resulting in altered pulmonary and immunologic function [8, 9], including a 20% 
increase in maternal oxygen consumption, a 10%–25% decrease in functional residual 
capacity, and significantly increased forced vital capacity after 14–16 weeks gestation. 
Severe respiratory illness during pregnancy may further disrupt maternal tolerance to 
hypoxemia and reduce oxygen flow to the fetus. Of 12 pregnant women infected with 
SARS-CoV in South China during 1 January–31 July 2003, spontaneous miscarriages were 
reported from over half (59%) of those infected during their first trimesters [10]. Premature 
deliveries, thought to be related to poor fetal oxygenation, were experienced among 80% of 
those women during their second to third trimesters and were associated with intrauterine 
growth restriction.
Further investigations in other settings of MERS-CoV infection outbreaks may shed light on 
factors related to the risk of infection and adverse birth outcomes in pregnant women, 
including any temporal relationship between maternal infection and period of gestation, 
biomarkers of immune hyperactivity, decreased respiratory function, and evidence of tissue 
necrosis upon hospitalization, as was observed during the epidemic of SARS-CoV infection 
to indicate adverse prognoses [11, 12]. Further information regarding the risk of MERS-
CoV–associated adverse consequences to mother and fetus during pregnancy, as well as the 
benefits and risks of possible therapies, is needed to better inform treatment decisions in 
pregnant women.
Although it is unclear whether cultural sensitivities restricted the full capture of information 
during our interviews, this was a joint investigation with the CDC and the Jordan Ministry 
of Health, and the interviewers included females from the region. All interviewers 
demonstrated an understanding of cultural sensitivities and spoke Arabic. A limitation of our 
report is that confirmation from seroepidemiologic evidence is difficult with any 
retrospective investigation, and associations between serologic evidence and a particular 
outcome can appear spurious. Indeed, the fetal loss rate from nonchromosomal and 
nonstructural causes at 20 weeks gestation is estimated to be 0.5% (95% confidence 
interval, .3%–.8%) [13] in developed countries, and other biological explanations for our 
observations are possible. Nonetheless, no other MERS-CoV infections were confirmed in 
Jordan around this brief outbreak period despite hundreds of specimens being tested via 
active surveillance [14]. On the basis of the exclusivity of the timing of the pregnant 
subject’s unprotected MERS-CoV exposure history, concurrent respiratory illness and 
stillbirth, and positive results of subsequent MERS-CoV serologic tests, we describe a 
possible association between MERS-CoV infection and stillbirth.
We conclude that adverse maternal and birth outcomes observed during the SARS-CoV 
epidemic and influenza A(H1N1) pandemic are consistent with the possibility that MERS-
CoV infection during pregnancy may pose serious health risks to both mother and fetus. The 
Kingdom of Saudi Arabia, where the majority of MERS-CoV cases have occurred, included 
pregnant women in its 2013 recommendation of groups that should “postpone the 
performance of Umrah and Hajj [in 2013]” [15]. Neither the CDC nor the WHO has issued 
evaluation or management strategy recommendations specifically for MERS-CoV infection 
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among pregnant women. As indicated by our investigation, MERS-CoV infections could 
potentially remain undetected among pregnant women because of barriers to receiving 
appropriate diagnostic care. Future prospective investigations of MERS-CoV should 
ascertain pregnancy status, and further pregnancy-related data should be obtained, including 
results of confirmatory testing of biological specimens.
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Timeline of events associated with a stillbirth attributable to Middle East respiratory 
syndrome coronavirus (MERS-CoV) infection, 1–30 April 2012.
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